REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no ...
Recursion Pharmaceuticals had aligned with the FDA on the design of its registrational Phase 3 trial of REC-4881, an ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
Recursion Pharmaceuticals, Inc () has held its Q3 earnings call. Read on for the main highlights of the call. Recursion Pharmaceuticals Earnings Call Highlights Clinical Momentum ...
Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...
With at least seven of its programs expected to begin human trials or read out clinical data during 2025, artificial intelligence (AI)-based drug developer Recursion Pharmaceuticals says it has begun ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results